Literature DB >> 17543872

Assessing malaria burden during pregnancy in Mali.

Kassoum Kayentao1, Mary Mungai, Monica Parise, Mamoudou Kodio, Abdoul Salam Keita, Drissa Coulibaly, Boubacar Maiga, Boubacar Traoré, Ogobara K Doumbo.   

Abstract

Malaria infection during pregnancy is associated with adverse consequences including low birth weight (LBW) and maternal anemia, particularly in primigravidae and secundigravidae. In preparation for a clinical trial of the efficacy of chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) containing prevention regimens during pregnancy, we conducted a one-year cross sectional study in Koro and Bandiagara, Mali using an assessment methodology developed by the Centers for Disease Control and Prevention (CDC) to generate basic data on malarial burden during pregnancy. Two hundred and sixty-one and 192 women were enrolled in Koro and Bandiagara, respectively. Rates of placental parasitemia were 17.1 and 42.3% in Koro and Bandiagara, respectively, despite high (70-80%) use of preventive medication (mainly CQ). Low gravidity (1st and 2nd pregnancies) was associated with peripheral (p<0.001) and placental (p<0.001) malaria only in Bandiagara, whereas it was associated with low birth weight in both sites (p<0.001 in Koro and p=0.002 in Bandiagara). First and second pregnancies were the most important characteristics associated with placental malaria (RR=2.78, 95%CI 1.81-4.29) and (ARR=2.06, 95%CI 1.03-4.15) and low birth weight (RR=4.26, 95%CI 2.50-7.27) and (ARR=4.51, 95%CI 2.55-8.00). Birth during the rainy season was associated with placental infection in univariate analysis. Characteristics such as younger age, having fever during pregnancy, and unmarried status were associated with low birth weight only in univariate analysis and singleton premature delivery and low gravidity were associated with low birth weight in both univariate and multivariate analysis. Data from this assessment demonstrated the high burden of malaria during pregnancy in Mali. Results had been used by researchers as local reference data and by ministry of health for to stop recommending CQ prophylaxis. The methodology could be used by other malaria-endemic countries to direct their national malaria program efforts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543872     DOI: 10.1016/j.actatropica.2007.04.005

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  9 in total

1.  Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.

Authors:  Wellington Aghoghovwia Oyibo; Chimere Obiora Agomo
Journal:  Matern Child Health J       Date:  2011-05

2.  Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.

Authors:  Innocent Valea; Halidou Tinto; Maminata Traore-Coulibaly; Laeticia C Toe; Niklas Lindegardh; Joel Tarning; Jean-Pierre Van Geertruyden; Umberto D'Alessandro; Geraint R Davies; Stephen A Ward
Journal:  J Antimicrob Chemother       Date:  2014-06-02       Impact factor: 5.790

3.  Parasitologic Assessment of Two-Dose and Monthly Intermittent Preventive Treatment of Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTP-SP) in Lagos, Nigeria.

Authors:  Chimere O Agomo; Wellington A Oyibo; Funke Odukoya-Maije
Journal:  Malar Res Treat       Date:  2011-10-26

4.  Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.

Authors:  Hamma Maiga; Abdoulaye A Djimde; Abdoul H Beavogui; Ousmane Toure; Mamadou Tekete; Cheick Papa O Sangare; Antoine Dara; Zoumana I Traore; Oumar B Traore; Souleymane Dama; Christelle N'Dong; Hamidou Niangaly; Nouhoum Diallo; Demba Dembele; Issaka Sagara; Ogobara K Doumbo
Journal:  Malar J       Date:  2015-02-07       Impact factor: 2.979

5.  [Factors associated with the failure of Intermittent Preventive Treatment for malaria among pregnant women in Yaounde].

Authors:  Félix Essiben; Pascal Foumane; Marcelle Aurelie Tsafack de Nguefack; Filbert Eko Eko; Philip Nana Njotang; Robinson Mbu Enow; Emile Telesphore Mboudou
Journal:  Pan Afr Med J       Date:  2016-03-31

6.  Factors Associated with Intermittent Preventive Treatment of Malaria During Pregnancy in Mali.

Authors:  Souleymane S Diarra; Drissa Konaté; Sory I Diawara; Mariam Tall; Mahamadou Diakité; Seydou Doumbia
Journal:  J Parasitol       Date:  2019-04       Impact factor: 1.276

7.  Risk factors for placental malaria, sulfadoxine-pyrimethamine doses, and birth outcomes in a rural to urban prospective cohort study on the Bandiagara Escarpment and Bamako, Mali.

Authors:  Claudius Vincenz; Zachary Dolo; Serou Saye; Jennie L Lovett; Beverly I Strassmann
Journal:  Malar J       Date:  2022-03-31       Impact factor: 2.979

8.  Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali.

Authors:  Kassoum Kayentao; Hamma Maiga; Robert D Newman; Meredith L McMorrow; Annett Hoppe; Oumar Yattara; Hamidou Traore; Younoussou Kone; Etienne A Guirou; Renion Saye; Boubacar Traore; Abdoulaye Djimde; Ogobara K Doumbo
Journal:  Malar J       Date:  2009-01-07       Impact factor: 2.979

9.  Epidemiology and aetiology of maternal parasitic infections in low- and middle-income countries.

Authors:  Tom Roberts; Courtney A Gravett; Prasad Palani Velu; Evropi Theodoratou; Thor A Wagner; Jian Shayne F Zhang; Harry Campbell; Craig E Rubens; Michael G Gravett; Igor Rudan
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.